A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Launched by CARMOT THERAPEUTICS, INC. · Mar 30, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CT-868 to see how it affects blood sugar control in people with Type 1 diabetes. The goal is to find out if this treatment can help maintain better glucose levels in participants. The study is currently looking for adults aged 18 to 65 who have had Type 1 diabetes for at least three years. To participate, individuals must be using either an insulin pump or multiple daily injections for managing their diabetes and have a body mass index (BMI) between 25 and 35.

Participants in this trial can expect to receive close monitoring and support throughout the study. It’s important to note that those with serious medical issues, uncontrolled diabetes, prior weight loss surgery, or a history of cancer will not be eligible to join. This research could provide valuable insights into new treatment options for managing Type 1 diabetes effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female or male adults with Type 1 diabetes
• • Ages 18-65 years
• • Type 1 DM for at least 3 years
• • Using an insulin pump or multiple daily injections (MDI) for at least 3 months
• • BMI 25.0 - 35.0
• Exclusion Criteria:
• • Significant medical history
• • Uncontrolled diabetes
• • History of surgical treatment for weight loss
• • History of malignancy